Adenosine-Based Approaches

The adenosine A2A receptor has received significant attention as a target for development of novel symptomatic therapies for PD. There is evidence that specific A2A antagonists reverse motor deficits and may alleviate dyskinesia in pre-clinical research models of PD (Xiao et al., 2006). Some pre-clinical research model studies suggest that A2A antagonists may also be neuroprotective (Schwarzchild et al., 2003). Several clinical trials have taken place using istradefylline, an A2A antagonist.
26 Oct 2009 03:21 PM EST
This paper further investigates the cellular mechanism of an adenosine A2A antagonist (SCH58261) in an MPTP mouse model of PD, utlizing pharmacologic and genetic methods. Carta et al. confirm the ... 
BASEL, Switzerland–(BUSINESS WIRE)– Synosia Therapeutics today announced interim positive data from a Phase IIa clinical study of an adenosine 2a (A2a) receptor antagonist (SYN115) in ... 
01 Feb 2010
31 May 2009
This study will evaluate the effects of an experimental drug called KW-6002 on Parkinson's disease symptoms and on dyskinesias (involuntary movements) that develop as a result of long-term treatment ... 
14 Jan 2008
This is an exploratory study to evaluate if SYN115 has an effect on Parkinson's disease as measured by clinical symptoms and brain images using magnetic resonance imaging (MRI) when a function test ... 
26 Sep 2007
The purpose of this study is to assess the long term safety of SCH 420814 in subjects with moderate to severe Parkinson's Disease who are taking a L-Dopa/dopa decarboxylase inhibitor ...